



StChristopher's
More than just a hospice

Emergencies in Palliative Care

Dr Alison Landon
October 2018

Introduction

- Patients in last year(s) of life may have reversible, treatable deteriorations some of which should be treated urgently
- Prompt / immediate diagnosis
- Potentially aggressive management.
- May create dissonance for staff or family.
- PC team must understand nature of emergencies and importance of emergency response

General Principles

- Rapid assessment, evaluation, and management of symptoms
- Rapid reversal of what is reversible
- Some acute events in palliative care have to be treated as an emergency if a favourable outcome is to be achieved
- Be aware of 'potential' emergencies
 - Focus on anticipating emergencies and ensuring an appropriate plan is in place in advance
 - Share plan with patient/family



Important Emergencies

- Hypercalcaemia
- Spinal cord /cauda equina Compression
- Respiratory distress (SVCO, non-malignant, effusions, stridor)
- Acute pain (Bone fractures)
- Neutropenic Sepsis
- Status Epilepticus
- Haemorrhage
- Anaphylaxis



Particularities to consider for each emergency situation

- Incidence
- Aetiology/patients at risk
- Clinical Presentation – Signs and Symptoms
- Investigations
- Management
- Outcomes



Hypercalcaemia

- Corrected plasma calcium concentration >2.6 mmol/l
- Most common tumour-induced metabolic disorder in malignancy
- 10 - 20% patients
- Most commonly associated with
 - squamous cell tumours e.g. breast, bronchus, head & neck, oesophagus
 - multiple myeloma, lymphomas
 - Bone metastases
 - Renal and genitourinary tumours

Hypercalcaemia - Aetiology

- Ectopic parathyroid hormone related protein (PTHrP)
- Locally active substances produced by bone metastases
- Ectopic cytokines
- Drugs e.g. thiazide diuretics and vit D and A supplements
- Increased osteoclastic activity (releases calcium from bone)
- Decreased excretion of urinary calcium
- Primary hyperparathyroidism - consider as differential especially if cancer otherwise stable

Hypercalcaemia – Clinical Presentation

- Often mild and can be asymptomatic
- Significant symptoms usually only develop with levels above 3.0 mmol/l
- Symptoms often proportional to rate of rise

Hypercalcaemia – Clinical Presentation

- Weakness/fatigue
- Loss of concentration
- Drowsiness
- Confusion
- Agitation
- Muscle spasms/tremors
- Anorexia
- Nausea
- Vomiting
- Thirst
- Polyuria
- Constipation
- Bone pain

Hypercalcaemia - Management

- Supportive care and symptom control
 - Antiemetics
 - Laxatives
 - Analgaesia
- Careful explanation
- Fluid replacement

Hypercalcaemia - Management

- Bisphosphonates
 - **Zoledronic acid** 4mg in 100mL sodium chloride 0.9% over 15 mins
 - **Pamidronate** 60-90mg in sodium chloride 0.9%, 500mL over 3-4 h
- Denosumab
- Calcitonin 800u/24h by **CSCI**

Hypercalcaemia - Management

- Normocalcaemia should be achieved in 3-7 days
- If calcium is not falling, repeat dose of bisphosphonate
- Mean length of response 2-4 weeks for pamidronate, 4-6 weeks for zoledronic acid.
- ? Check serum calcium every 2 weeks.
- ? Maintenance therapy after two episodes
 - pamidronate 90mg **IV** every 4 weeks, or
 - zoledronic acid 4mg **IV** every 4 weeks, or
 - ibandronic acid **IV** or **PO**

Hypercalcaemia - Outcomes

- Associated with a poor prognosis
- 80% of hypercalcaemic patients with cancer survive less than one year
- Levels of 4.0 mmol/l and above will cause death in a few days if left untreated

Spinal Cord Compression

- Indentation(s) of the spinal cord or cauda equina (if below L1/L2)
- Pressure from metastatic spread to / around the spine (or less commonly by a primary)
- Potentially with accompanying vertebral collapse / instability
- Threatens or is causing neurological disability

Spinal Cord Compression – Incidence

- 5-10% of cancer patients with cancer
- Incidence increasing with advances in cancer treatment
- 10% of patients will have compression >1 site
- Immediately pre-treatment neurological function is the most powerful predictor of outcome
 - 70% thoracic spine
 - 10% cervical spine
 - 20% lumbar spine

Spinal Cord Compression - Aetiology

- Compression of the spinal cord → neurological dysfunction / damage, altering transmission of impulses to & from the brain, can lead eventually to paraplegia or quadriplegia
- >75% of MSCC secondary to extradural compression from bone metastases in the vertebrae
- epidural disease (blood borne metastasis or extension from a vertebral metastasis)
- vertebral collapse

Spinal Cord Compression – Clinical Presentation

- Symptoms and signs seen will depend on the site (spinal level) of compression
- Symptoms include: back pain, limb weakness, sensory loss and bladder or bowel dysfunction
- Many patients present initially with symptoms suggestive of spinal metastases
- Distinguishing the symptoms of spinal metastases from neurological symptoms or signs suggestive of **MSCC** will dictate the urgency of subsequent management

Symptoms suggestive of spinal metastases

- Increasing pain in thoracic or cervical spine
- Progressive lumbar spinal pain
- Severe unremitting lumbar spinal pain
- Spinal pain aggravated by straining
- Localised spinal tenderness
- Nocturnal spinal pain preventing sleep

Neurological symptoms/signs suggestive of Spinal Cord Or Cauda Equina Compression

- Radicular pain: radiates in distribution of nerve(s) e.g. 'band like' pain/ tightness around the chest (90%)
- Limb weakness e.g. heaviness of legs (75%)
- Difficulty walking or history of recent falls
- Sensory loss e.g. new feelings of clumsiness / weakness /falls
- Bladder or bowel dysfunction (40%)
- Other signs e.g. clonus or a sensory level (50%)

Spinal Cord Compression - Management

*** Treatment outcome is better, the earlier it is started ***

- Offer URGENT admission
- URGENT whole spine MRI (ideally within 24 hours)
- If **MRI** contraindicated, consider whole spine **CT**
- Nurse lying flat (supine) / log roll
- If neck pain consider cervical-spine immobilisation with Miami-J collar
- Dexamethasone 8mgs b.d. ± PPI cover (Monitor BM)
- Consider thromboprophylaxis
- Appropriate analgesia

Confirmed or impending MSCC

- Careful explanation
- Cont treatment as above
- Consider urgent referral/discussion with spinal surgeons
- Urgent (within 24 hrs) discussion with oncologist regarding radiotherapy.

Spinal cord compression - Management

- Urgent, fractionated radiotherapy (within 24 hours) if unsuitable for surgery unless:
 - complete paraplegia or tetraplegia for >24 hours and pain well controlled, or...
 - their prognosis is too poor
- Urgent referral to physiotherapy to assess spinal stability and commence appropriate rehabilitation
- Support services for assessment, advice and rehabilitation

Steroid Management

- After surgery or radiotherapy, gradually reduce dose of dexamethasone after 4 to 5 days
- Follow local guidelines OR halve total daily dexamethasone dose every 4 to 5 days
 - 16mg to 8 mg to 4mg to 2mg to 1mg
 - 1mg alternate days for 4 to 5 days
- Review neurological function
- If neurological function worsens, increase steroid dose to previous dose where function was stable, continue for 2 weeks, before attempting reduction again.

Spinal cord compression - Management

- Malignant spinal cord compression (**MSCC**) co-ordinator
- Deciding the best course of treatment for a particular patient requires an overall assessment to include
 - patient wishes
 - Prognosis
 - Performance status
 - Co-morbidities
 - Oncology disease status
- **NICE** cautions against unnecessary investigation of patients too frail or unfit for specialist treatment

Ongoing Management

- Mobility management
- Skin care
- Bowel interventions
- Urinary system management
- Psychosocial support
- Social and financial issues

Spinal Cord Compression - Outcomes

- 30% patients with **MSCC** survive >1year
- Median survival 7-10 months
- Immediately pre-treatment neurological function most powerful predictor of outcome
- Function retained in ~70% patients ambulant prior to treatment, but will return in ~ 5% of those who were paralysed at the outset
- Hours can potentially make a difference to chance a patient remains able to walk or be continent
- Delays in starting treatment can result in irreversible neurological damage

Neutropenic Sepsis

- Life-threatening
 - 'symptoms or signs associated with infection
 - neutrophil count $<1.0 \times 10^9/L$
 - typically complication of chemotherapy
 - can result in rapid clinical deterioration and death
 - Often the earliest and only sign may be a fever
- Well-recognised but often poorly managed

Early Onset Symptoms

- Chest Pain/Breathing Difficulties
- Temp $>38^{\circ}\text{C}$
- Shivering
- Flu-like Symptoms
- Gum/Nose Bleeds
- Unusual Bruising
- Mouth Ulcers
- Vomiting
- Diarrhoea

Late Stage Symptoms

- Restlessness
- Change in Conscious Level
- Cold/Clammy
- Hypotension
- Hypothermia
- Tachycardia

Neutropenic Sepsis

- Low index suspicion
- Contact oncology centre urgently
- Rapid assessment and treatment is imperative
- **IV** antibiotics required within 60 mins
- Urgently transfer to acute inpatient setting
- Do not delay initiation of treatment, including empirical antibiotics

Massive Haemorrhage

- Incidence 6 – 14% in adult patients with advanced cancer
- Can be terminal event
- Very frightening for the patient, family and carers.
- Identifying patients with potential risk of major haemorrhage should prompt advance care planning alongside the patient, their family and carers

Massive haemorrhage - Predisposing factors

- Cancer related - abnormal clotting, platelet dysfunction
- Chemotherapy related – reduced platelet count
- Biochemical –hepatic dysfunction
- Pharmacological – NSAIDS, anticoagulants
- Tumour invasion – haemoptysis, carotid ‘blow-out’, GI bleed
- Herald bleeds

Treatment of minor bleeds

- Radiotherapy
- Adrenaline, Tranexamic acid, Ethamsylate (topical)
- Systemic tranexamic acid (check C/I)
- Haemostatic dressings
- If major haemorrhage is anticipated
 - dark towels, gloves, suction
 - appropriate drugs (drawn up in syringe) kept available by the bedside

Massive Haemorrhage – Should we discuss??

- Consider in advance
- Discussing issues of resuscitation
- Use of sedation, prophylactically and in the acute situation
- Whether family would/or would not want to be present
- Sensitive Communication
- To tell or not to tell

Massive Haemorrhage

- By definition, terminal event
- Aim of treatment is to sedate as quickly as possible to relieve patient distress
- Speed (access to drug, and administration) is paramount
- Give drugs **IV** if at all possible; if not, deep **IM**
 - ⇒ Stay with the patient
 - ⇒ Stay calm
 - ⇒ Supply of dark towels available

Massive Haemorrhage

- Drug doses for rapid terminal sedation
 - Ketamine 150mg - 250mg IV or 500mg IM
 - Midazolam 30mg – 50mg IV or 20mg – 30mg IM
- If haemorrhage is brisk, but not inevitably and rapidly fatal, use lower doses appropriate for managing distress i.e. midazolam 5-10mg IM

Superior Vena Cava Obstruction (SVCO)

- Impaired blood flow through the superior vena cava (**SVC**)
- SVCO is due to compression, obstruction or thrombosis impairing central venous return which leads to a build up of pressure behind the blockage
- Mediastinal lymph nodes or tumour in the region of the right main bronchus
- Fluid then seeps out from the bloodstream and collects in the tissues of the face.

SVCO Incidence

- Rare
- 5-10% patients with cancer R lung
 - Carcinoma of bronchus (75%)
 - Lymphomas (15%)
 - Cancers of breast, colon, oesophagus and testis
 - Non-malignant causes 5 – 10 %

SVCO – Clinical presentation

- Breathlessness (laryngeal oedema)
- Headache (cerebral oedema)
- Visual changes
- Dizziness
- Hoarse voice
- Swelling of face, neck and arms
- Engorged conjunctivae
- Peri-orbital oedema
- Non-pulsatile dilated neck veins
- Dilated collateral veins (chest and arms)

SVCO - Management

- Investigations
 - CXR, USS, MRI, CT
- Upright position
- Oxygen
- Dexamethasone 16mg
- Furosemide 40mg
- Low-dose morphine 2.5 - 5mg 4-hourly for breathlessness
- Maintain calmness / consider low-dose anxiolytic

SVCO - Management

- **Radiotherapy** - short course
- **Chemotherapy** if tumours are sensitive e.g. lymphoma small cell lung cancer, breast cancer
- **Stent** – Intraluminal stent, inserted via the femoral vein
- **Anti-coagulants** - if SVCO caused by a clot

SVCO - Outcomes

- Poor prognosis
- Without treatment, can progress over several days leading to death
- With treatment
 - Average survival 8 months
 - 17% alive after 1year
- Prognosis worse when primary cancer causing the **SVCO** not responsive to radiotherapy or chemotherapy

Convulsions & Seizures

- Primary or secondary brain tumours
- Metabolic complications
 - Hyponatremia
 - Hypoglycaemia
 - Hypercalcaemia
 - Pre-existing epilepsy
 - Cerebrovascular disease

Emergency Management of Acute Seizures

- Safe positioning - recovery position
- Maintain airway
- Consider rapidly treatable causes e.g. hypoglycaemia
- Administration of anticonvulsant if seizure does not resolve within 5 minutes:

Management of Seizures

- Midazolam 10mg buccal / 5-10mg SC/IM
- Diazepam 10mg PR
- Lorazepam 4mg slow IV (< 2mg/min)

- Repeat once after 15-20 mins if seizures persist

- N.B. Support relatives

Prolonged Seizures

- Consider transfer to acute hospital if appropriate
- If not for transfer, treat refractory seizures with:
 - midazolam 20-30mg SC over 24 hours via syringe pump and titrate
 - phenobarbital 100–200mg IM stat followed by 200-600mg CSCI/24hrs

Status Epilepticus

- Midazolam 5mg slow IV titration.
 - lorazepam 4mg slow IV
 - Diazepam 10mg slow IV
 - clonazepam 1mg slow IV (into large vein)
- Repeat dose if needed after 10 minutes
- If no response to repeat dose or seizures recur
 - Phenobarbital 200mg slow IV
 - Repeat up to max 10-15mg/kg (600mg - 1000mg) at max rate of 100mg/minute

N.B. Once seizures have been controlled, review anticonvulsant therapy

Anaphylaxis

1. Sudden onset and rapid progression of symptoms
2. Life-threatening compromise of
 - airway and/or
 - breathing and/or
 - Circulation
3. Skin and/or mucosal changes
 - flushing
 - urticaria
 - angioedema

Anaphylaxis – Treatment guidelines

- ABCDE approach to assess and treat
 - Airway
 - Breathing
 - Circulation
 - Disability
 - Exposure
- Treat life-threatening problems as found
- Monitor patient closely - pulse oximetry, non-invasive blood pressure +/- 3-lead ECG

Anaphylaxis

- Adrenaline
 - 0.5ml of 1:1,000 adrenaline (0.5mg) IM
 - Repeat at 5-minute intervals if no improvement
- Comfortable position
- Oxygen (high flow)
- Fluids (rapid IV fluid challenge of 500–1,000ml)
- Antihistamines
 - 10mg chlorphenamine **IM** or slow **IV**
- Corticosteroids
 - 200mg hydrocortisone **IM** or slow **IV**

Conclusions

- Patients in last year of life may have reversible, treatable deteriorations some of which should be treated urgently
- Cord/cauda compression needs early identification as delays worsen outcome and quality of life
- High risk patients (prostate, kidney, breast, myeloma) and their carers should be made aware of warning signs of compression
- Low index of suspicion - do not delay starting high dose steroids

Conclusions

- Many chemotherapy patients do not remember that they are at risk of neutropenic sepsis. Beware the 7-10 day post chemo nadir.
- Treatment in oncology centre or acute hospital
- Treating hypercalcaemia can cause significant improvement in symptoms
- Haemorrhage and status epilepticus may be too distressing to manage at home - low threshold for hospice/hospital admission